Relative risk of outcomes in patients who received IFN- versus patients who did not receive IFN- before HLA-identical sibling transplantation for chronic-phase CML
| Outcome . | Relative Risk3-150 . | 95% Confidence Interval . | P . |
|---|---|---|---|
| Relapse3-151 | 0.17 | 0.04-0.70 | .01 |
| Nonrelapse mortality3-152 | 1.21 | 0.89-1.65 | .22 |
| Treatment failure (relapse or death)3-153 | 0.99 | 0.73-1.33 | .92 |
| Outcome . | Relative Risk3-150 . | 95% Confidence Interval . | P . |
|---|---|---|---|
| Relapse3-151 | 0.17 | 0.04-0.70 | .01 |
| Nonrelapse mortality3-152 | 1.21 | 0.89-1.65 | .22 |
| Treatment failure (relapse or death)3-153 | 0.99 | 0.73-1.33 | .92 |
Relative risk in persons who received IFN-α before transplantation compared with patients who did not receive IFN-α.
Adjusted for conditioning regimen.
Adjusted for age, year of transplantation, platelet count at diagnosis, donor-recipient sex match, and prophylaxis for graft-versus-host disease (GVHD).
Adjusted for age, year of transplantation, platelet count at diagnosis, conditioning regimen, GVHD prophylaxis, and race.